Robert Bell is the co-founder and CEO of Telo Therapeutics Inc., an oncology therapeutics company that utilizes novel precision medicine approaches to reverse cancer cell immortality. The company’s core pipeline focuses on cancer cell-specific inhibitors of telomerase. Dr. Bell earned his BS from Boston College and his PhD in Biomedical Sciences from the University of California, San Francisco. Telo was founded in 2015 based on Dr. Bell’s graduate work and was incubated at MBC Biolabs in San Francisco. In June, Telo raised $6 Million in Series Seed financing that will be used to develop its small molecule inhibitors towards clinical candidates directed towards Glioblastoma and other cancer types with high unmet need.